PMID- 34926238
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220429
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Multi-Phase CT-Based Radiomics Nomogram for Discrimination Between Pancreatic 
      Serous Cystic Neoplasm From Mucinous Cystic Neoplasm.
PG  - 699812
LID - 10.3389/fonc.2021.699812 [doi]
LID - 699812
AB  - PURPOSE: This study aimed to develop and verify a multi-phase (MP) computed 
      tomography (CT)-based radiomics nomogram to differentiate pancreatic serous 
      cystic neoplasms (SCNs) from mucinous cystic neoplasms (MCNs), and to compare the 
      diagnostic efficacy of radiomics models for different phases of CT scans. 
      MATERIALS AND METHODS: A total of 170 patients who underwent surgical resection 
      between January 2011 and December 2018, with pathologically confirmed pancreatic 
      cystic neoplasms (SCN=115, MCN=55) were included in this single-center 
      retrospective study. Radiomics features were extracted from plain scan (PS), 
      arterial phase (AP), and venous phase (VP) CT scans. Algorithms were performed to 
      identify the optimal features to build a radiomics signature (Radscore) for each 
      phase. All features from these three phases were analyzed to develop the 
      MP-Radscore. A combined model comprised the MP-Radscore and imaging features from 
      which a nomogram was developed. The accuracy of the nomogram was evaluated using 
      receiver operating characteristic (ROC) curves, calibration tests, and decision 
      curve analysis. RESULTS: For each scan phase, 1218 features were extracted, and 
      the optimal ones were selected to construct the PS-Radscore (11 features), 
      AP-Radscore (11 features), and VP-Radscore (12 features). The MP-Radscore (14 
      features) achieved better performance based on ROC curve analysis than any single 
      phase did [area under the curve (AUC), training cohort: MP-Radscore 0.89, 
      PS-Radscore 0.78, AP-Radscore 0.83, VP-Radscore 0.85; validation cohort: 
      MP-Radscore 0.88, PS-Radscore 0.77, AP-Radscore 0.83, VP-Radscore 0.84]. The 
      combination nomogram performance was excellent, surpassing those of all other 
      nomograms in both the training cohort (AUC, 0.91) and validation cohort (AUC, 
      0.90). The nomogram also performed well in the calibration and decision curve 
      analyses. CONCLUSIONS: Radiomics for arterial and venous single-phase models 
      outperformed the plain scan model. The combination nomogram that incorporated the 
      MP-Radscore, tumor location, and cystic number had the best discriminatory 
      performance and showed excellent accuracy for differentiating SCN from MCN.
CI  - Copyright (c) 2021 Gao, Han, Wang, Duan and Zhang.
FAU - Gao, Jiahao
AU  - Gao J
AD  - Department of Radiology, Huashan Hospital North, Fudan University, Shanghai, 
      China.
AD  - Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China.
FAU - Han, Fang
AU  - Han F
AD  - Department of Radiology, Huashan Hospital North, Fudan University, Shanghai, 
      China.
AD  - Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China.
FAU - Wang, Xiaoshuang
AU  - Wang X
AD  - Department of Radiology, Huashan Hospital North, Fudan University, Shanghai, 
      China.
FAU - Duan, Shaofeng
AU  - Duan S
AD  - Department of Life Sciences, GE Healthcare, Shanghai, China.
FAU - Zhang, Jiawen
AU  - Zhang J
AD  - Department of Radiology, Huashan Hospital North, Fudan University, Shanghai, 
      China.
AD  - Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20211201
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8672034
OTO - NOTNLM
OT  - contrast-enhanced computed tomography (CECT)
OT  - nomogram
OT  - pancreatic cystic neoplasm
OT  - radiomics
OT  - texture analysis
COIS- Author SD was employed by GE Healthcare. The remaining authors declare that the 
      research was conducted in the absence of any commercial or financial 
      relationships that could be construed as a potential conflict of interest.
EDAT- 2021/12/21 06:00
MHDA- 2021/12/21 06:01
PMCR- 2021/01/01
CRDT- 2021/12/20 06:17
PHST- 2021/04/24 00:00 [received]
PHST- 2021/11/15 00:00 [accepted]
PHST- 2021/12/20 06:17 [entrez]
PHST- 2021/12/21 06:00 [pubmed]
PHST- 2021/12/21 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.699812 [doi]
PST - epublish
SO  - Front Oncol. 2021 Dec 1;11:699812. doi: 10.3389/fonc.2021.699812. eCollection 
      2021.